IMUX - Immunic Inc Stock Price, Fair Value and News

$1.00-0.04 (-3.85%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

IMUX Price Action

Last 7 days

-11.5%

Last 30 days

-6.5%

Last 90 days

-45.4%

Trailing 12 Months

-28.6%

IMUX RSI Chart

IMUX Valuation

Market Cap

90.1M

Price/Earnings (Trailing)

-0.93

Price/Sales (Trailing)

6.16

Price/Free Cashflow

-1.18

IMUX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

IMUX Fundamentals

IMUX Revenue

Revenue (TTM)

17.3M

IMUX Earnings

Earnings (TTM)

-96.9M

Earnings Growth (Yr)

-7.02%

Earnings Growth (Qtr)

-13.98%

IMUX Profitability

Return on Equity

-235.1%

Return on Assets

-149.63%

Free Cashflow Yield

-84.65%

IMUX Investor Care

Shares Dilution (1Y)

99.53%

Diluted EPS (TTM)

-1.23

IMUX Alerts

JANUS HENDERSON GROUP PLC reported owning 5.7% of IMUX [2024-11-14]
1 major insider buys recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2021	0	0	0	17.3M

Get all data in R, Python etc through our Historical Stock Data APIs

About Immunic Inc

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 3 clinical for treatment of multiple sclerosis, including relapsing multiple sclerosis and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

CEO	Dr. Daniel Vitt Ph.D.
WEBSITE	imux.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	75

Immunic Inc Frequently Asked Questions

What is the ticker symbol for Immunic Inc? What does IMUX stand for in stocks?

IMUX is the stock ticker symbol of Immunic Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Immunic Inc (IMUX)?

As of Fri Dec 20 2024, market cap of Immunic Inc is 90.08 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IMUX stock?

You can check IMUX's fair value in chart for subscribers.

Is Immunic Inc a good stock to buy?

The fair value guage provides a quick view whether IMUX is over valued or under valued. Whether Immunic Inc is cheap or expensive depends on the assumptions which impact Immunic Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IMUX.

What is Immunic Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, IMUX's PE ratio (Price to Earnings) is -0.93 and Price to Sales (PS) ratio is 6.16. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IMUX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Immunic Inc's stock?

In the past 10 years, Immunic Inc has provided -0.499 (multiply by 100 for percentage) rate of return.